Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
January 13 2022 - 4:34PM
Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapeutics and vaccines, today announced it will host a
virtual Key Opinion Leader (“KOL”) event on VTP-300, in development
as a key component of a functional cure therapy for chronic
hepatitis B (CHB) infection, and the broader CHB therapeutics
landscape. The event will be webcast live on January 25th at 8:30
a.m. EST.
Featured speakers:
- Dr. Kaushik Agarwal,
consultant hepatologist and transplant physician at the Institute
of Liver Studies at King’s College Hospital, Viral Hepatitis
Service lead, and Director of the NIHR South London Clinical
Research Network.
- Dr. Henry L. Y.
Chan, head of the Division of Gastroenterology and Hepatology,
Director of the Institute of Digestive Disease, the Center for
Liver Health, and the Office of Global Engagement. Dr. Chan is also
the Assistant Dean of External Affairs for the Faculty of Medicine
at CUHK and the Course Director for the Master of Science in
Gastroenterology at CUHK.
Vaccitech’s Virtual KOL Event details are as follows:
- Tuesday, January
25th, 2022, 8:30 a.m. EST – 10:00 a.m. EST
- To join the webcast,
please visit the Events section of the Investor Relations page of
the Company’s website at:
https://investors.vaccitech.co.uk/news-and-events/events
- A replay of the
webcast will be available at the same location
About Vaccitech plc
Vaccitech (“the Company”) is a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapies and vaccines for the treatment and prevention of
infectious disease, cancer, and autoimmune disease. The company’s
proprietary platforms comprise modified simian adenoviral vectors,
known as ChAdOx1 and ChAdOx2, the well-validated Modified Vaccinia
Ankara, or MVA, all of which lack the ability to replicate in
humans, and the SNAPvax™ and Syntholytic™ polymer-based platforms.
The company has a broad pipeline of both clinical and preclinical
stage therapeutic programs in solid tumors, viral infections,
autoimmunity, and prophylactic viral vaccine programs. Vaccitech
co-invented a COVID-19 vaccine with the University of Oxford, now
approved for use in many territories and exclusively licensed
worldwide to AstraZeneca through Oxford University Innovation, or
OUI. Vaccitech is entitled to receive a share of the milestones and
royalty income received by OUI from AstraZeneca.
Forward Looking Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, express or implied
statements regarding: the clinical trials of ChAdOx1-HBV and the
ChAdOx1-HBV/MVA-HBV (VTP-300) and low-dose nivolumab combination,
the continued development of VTP-300 and the potential therapeutic
effects and expected patient population of VTP-300. The words
“may,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to
numerous risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation: the success, cost and
timing of the Company’s product development activities and planned
and ongoing clinical trials, the Company’s ability to execute on
its strategy, regulatory developments, the Company’s ability to
fund its operations and the impact that the current COVID-19
pandemic will have on the Company’s clinical trials and preclinical
studies and other risks identified in the Company’s filings with
the Securities and Exchange Commission (the “SEC”), including its
Quarterly Report on Form 10-Q for the first quarter of 2021 and
subsequent filings with the SEC. The Company cautions you not to
place undue reliance on any forward-looking statements, which speak
only as of the date they are made. The Company expressly disclaims
any obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements.
Media contacts:
Katja Stout, Scius Communications (EU)Direct: +44 (0) 7789 435
990Email: katja@sciuscommunications.com
Katie Larch / Robert Flamm, Ph.D. (US)Burns McClellan,
Inc.Email: klarch@burnsmc.com / rflamm@burnsmc.com
Henry Hodge, VaccitechEmail: henry.hodge@vaccitech.co.uk
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Sep 2023 to Sep 2024